Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478296 | 1.00 | SLC6A2 (0.48) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL14478271 | 1.00 | SLC6A2 (0.48) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL20544474 | 0.86 | TAAR1 (0.52) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL4745252 | 0.82 | IDO1 (0.40) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL17407620 | 0.82 | DPP4 (0.52) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL1530031 | 0.80 | PNMT (0.60) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL14478266 | 0.80 | PNMT (0.60) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL29410132 | 0.80 | PNMT (0.60) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL2561950 | 0.80 | PNMT (0.60) | SLC6A2TAAR1SLC6A3MAOASLC6A4 | |
| SCHEMBL2623872 | 0.80 | IDO1 (0.41) | MAOAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828345-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | SLC6A2 2468/4885TAAR1 3257/4885SLC6A3 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.